Therapeutics: Human cytomegalovirus (CMV) type 2 membrane protein (UL50); CMV type 3 membrane protein (UL53)

In vitro studies suggest disrupting UL50-UL53 binding could help treat CMV infection. Mutagenesis of UL50 followed by an in vitro UL50-UL53 binding assay identified three mutant forms of the protein, ...